Vascular Endothelial Growth Factor Bioactivity and Its Receptors in Patients with Acute Respiratory Distress Syndrome
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Pathogenesis of acute respiratory distress syndrome (ARDS) is a controversial issue. Few studies have analyzed the possible role of vascular endothelial growth factor (VEGF) and its receptors in this lesion. Methods: We compared the immunohistochemical expression of VEGF, its receptors (VEGFR1, VEGFR2) and CD68, in normal lungs and lungs with ARDS. Fifty necropsy cases and 12 lung biopsies with ARDS were analyzed. In total, eight cases were in the early stage and 54 cases were in late stage of ARDS. In addition, the serum level of VEGF165 was also determined. Results: In normal lungs, all antibodies marked the endothelial cells (EC) and pneumocytes (PC), except for CD68, which was expressed in the alveolar macrophages. In early ARDS, the intensity of VEGF165 and VEGFR2 decreased in both EC and PC. VEGF121 was absent in PC but its expression increased in bronchial epithelium. VEGFR1 was expressed in the integral PC. In late ARDS, VEGF165 down-regulation was more significant in PC and EC but its intensity increased in hyaline membranes (HM). In some cases, HM were CD68 positive. The serum level of VEGF165 was up-regulated, while VEGF165 intensity in PC decreased and the HM appeared in alveolar spaces. Conclusions: Sporadic positivity of HM for CD68 and decreasing of VEGF165 expression in EC proved that VEGF165 is produced by PC, destroyed macrophages, and extravasated serum.
Abstract
Background: Pathogenesis of acute respiratory distress syndrome (ARDS) is a controversial issue. Few studies have analyzed the possible role of vascular endothelial growth factor (VEGF) and its receptors in this lesion. Methods: We compared the immunohistochemical expression of VEGF, its receptors (VEGFR1, VEGFR2) and CD68, in normal lungs and lungs with ARDS. Fifty necropsy cases and 12 lung biopsies with ARDS were analyzed. In total, eight cases were in the early stage and 54 cases were in late stage of ARDS. In addition, the serum level of VEGF165 was also determined. Results: In normal lungs, all antibodies marked the endothelial cells (EC) and pneumocytes (PC), except for CD68, which was expressed in the alveolar macrophages. In early ARDS, the intensity of VEGF165 and VEGFR2 decreased in both EC and PC. VEGF121 was absent in PC but its expression increased in bronchial epithelium. VEGFR1 was expressed in the integral PC. In late ARDS, VEGF165 down-regulation was more significant in PC and EC but its intensity increased in hyaline membranes (HM). In some cases, HM were CD68 positive. The serum level of VEGF165 was up-regulated, while VEGF165 intensity in PC decreased and the HM appeared in alveolar spaces. Conclusions: Sporadic positivity of HM for CD68 and decreasing of VEGF165 expression in EC proved that VEGF165 is produced by PC, destroyed macrophages, and extravasated serum.
참고문헌 (27)
- Medford AR, "Vascular endothelial growth factor receptor and coreceptor expression in human acute respiratory distress syndrome", J Crit Care, 24, pp.236~242 (2009)
- Perkins GD, "Regulation of vascular endothelial growth factor bioactivity in patients with acute lung injury", Thorax, 60, pp.153~158 (2005)
- Mura M, "Vascular endothelial growth factor and related molecules in acute lung injury", J Appl Physiol, 97, pp.1605~1617 (2004)
- Medford AR, "Vascular endothelial growth factor (VEGF) in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): paradox or paradigm", Thorax, 61, pp.621~626 (2006)
- Kuhn H, "High concentrations of vascular endothelial growth factor reduce stretch-induced apoptosis of alveolar type II cells", Respirology, 15, pp.343~348 (2010)
- Kaner RJ, "Compartmentalization of vascular endothelial growth factor to the epithelial surface of the human lung", Mol Med, 7, pp.240~246 (2001)
- Thickett DR, "Vascular endothelial growth factor may contribute to increased vascular permeability in acute respiratory distress syndrome", Am J Respir Crit Care Med, 164, pp.1601~1605 (2001)
- Abadie Y, "Decreased VEGF concentration in lung tissue and vascular injury during ARDS", Eur Respir J, 25, pp.139~146 (2005)
- Mazure NM, "Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase", Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element, 1997, pp.90, 3322~3331
- Camera M, "Cooperation between VEGF and TNF-alpha is necessary for exposure of active tissue factor on the surface of human endothelial cells", Arterioscler Thromb Vasc Biol, 19, pp.531~537 (1999)
- Epiphanio S, "VEGF promotes malaria-associated acute lung injury in mice", PLoS Pathog, 6, pp.e1000916~ (2010)
- Zheng W, "Mechanisms of coronary angiogenesis in response to stretch: role of VEGF and TGF-beta", Am J Physiol Heart Circ Physiol, 280, pp.H909~H917 (2001)
- Medford AR, "Vascular endothelial growth factor (VEGF) isoform expression and activity in human and murine lung injury", Respir Res, 10, pp.27~ (2009)
- Tischer E, "The human gene for vascular endothelial growth factor: multiple protein forms are encoded through alternative exon splicing", J Biol Chem, 266, pp.11947~11954 (1991)
- Houck KA, "Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms", J Biol Chem, 267, pp.26031~26037 (1992)
- Ferrara N, "The biology of VEGF and its receptors", Nat Med, 9, pp.669~676 (2003)
- Keyt BA, "The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency", J Biol Chem, 271, pp.7788~7795 (1996)
- Zachary I, "Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family", Cardiovasc Res, 49, pp.568~581 (2001)
- Robinson CJ, "The splice variants of vascular endothelial growth factor (VEGF) and their receptors", J Cell Sci, 114(Pt 5), pp.853~865 (2001)
- Shalaby F, "Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice", Nature, 376, pp.62~66 (1995)
- Fong GH, "Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice", Development, 126, pp.3015~3025 (1999)
- Bernard GR, "The American-European Consensus Conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination", Am J Respir Crit Care Med, 149(3 Pt 1), pp.818~824 (1994)
- Azamfirei L, "Vascular endothelial growth factor: a possible mediator of endothelial activation in acute respiratory distress syndrome", Minerva Anestesiol, 76, pp.609~616 (2010)
- Maitre B, "Vascular endothelial growth factor synthesis in the acute phase of experimental and clinical lung injury", Eur Respir J, 18, pp.100~106 (2001)
- Koh H, "Vascular endothelial growth factor in epithelial lining fluid of patients with acute respiratory distress syndrome", Respirology, 13, pp.281~284 (2008)
- Compernolle V, "Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice", Nat Med, 8, pp.702~710 (2002)
- Ohwada A, "VEGF regulates the proliferation of acid-exposed alveolar lining epithelial cells", Thorax, 58, pp.328~332 (2003)